Why is the PolyNovo share price surging 13% higher today?

PolyNovo shares are on fire on Wednesday…

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • PolyNovo's shares are shooting higher on Wednesday morning
  • This follows the release of a strong third quarter update
  • The medical device company also revealed that its balance sheet has strengthened

The PolyNovo Ltd (ASX: PNV) share price is on the rise on Wednesday morning.

At the time of writing, the medical device company's shares are up 13% to $1.22.

Why is the PolyNovo share price on the move?

Investors have been bidding the PolyNovo share price higher following the release of a third quarter update.

According to the release, PolyNovo delivered unaudited revenue of A$12.26 million during the third quarter of FY 2022. This represents a 59.3% increase on the revenue of A$7.69 million reported during the prior corresponding period.

This reflects a 79.4% increase in US sales to a record US$6.89 million (A$9.53 million) and an 81.9% lift in ANZ sales to A$1.16 million. It also includes income of A$1 million relating to BARDA and A$0.1 million from a Victorian State Government grant.

This means that PolyNovo's year to date revenue is now A$30.4 million, which implies an annual run rate of A$48 million.

PolyNovo's Chair, David Williams, explained that this result was driven by an increase in its salesforce and easing COVID-19 headwinds.

He said "More sales reps equals a wider geographical footprint and increased sales. More reps and the diminishing effects of Covid, have driven record sales in US, UKI and Australia."

What else?

One thing that has been weighing on the PolyNovo share price this year has been concerns over its dwindling cash balance and the potential requirement of a capital raising in the near future.

Positively, the heavily shorted company's cash balance increased during the third quarter even before taking into account the sale of its Lorimer Street property.

At the end of March, PolyNovo had cash of A$3.8 million, which was up A$0.5 million since the end of December. This will soon be boosted by a further A$6.35 million from the Lorimer Street property sale when the process completes in June.

Finally, management advised that its clinical trial programmes remain on track. This includes recruitment for the pivotal burn trial and enrolment of the first patients for the DFU trial.

PolyNovo is also on track to file for the 510K approval for the Matrix product during this financial year and work on the prototypes for Hernia development and new designs for BTM are also on track.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »